

Shengtao Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1591696/publications.pdf>

Version: 2024-02-01

49
papers

2,212
citations

279798

23
h-index

233421

45
g-index

51
all docs

51
docs citations

51
times ranked

3756
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 27.	19.2	35
2	The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. <i>Molecular Cancer</i> , 2022, 21, 30.	19.2	26
3	Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. <i>Oncogene</i> , 2022, 41, 895-906.	5.9	22
4	An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway. <i>Cancer Gene Therapy</i> , 2021, 28, 112-125.	4.6	19
5	Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges. <i>Trends in Cancer</i> , 2021, 7, 541-556.	7.4	11
6	Sequential fate-switches in stem-like cells drive the tumorigenic trajectory from human neural stem cells to malignant glioma. <i>Cell Research</i> , 2021, 31, 684-702.	12.0	41
7	Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. <i>Science Advances</i> , 2021, 7, .	10.3	25
8	Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4523.	4.1	11
9	OCaMIRs: A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study. <i>Clinical Cancer Research</i> , 2021, 27, 4277-4286.	7.0	14
10	Spatially resolved proteomics identify biomarkers from endometrial sentinel lymph nodes. <i>Cell Reports Medicine</i> , 2021, 2, 100283.	6.5	1
11	Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. <i>Oncogene</i> , 2021, 40, 6059-6070.	5.9	13
12	Immunoregulatory Functions of Nuclear Receptors: Mechanisms and Therapeutic Implications. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 93-106.	7.1	5
13	Multiomics kaleidoscope to visualize cancer hallmarks. <i>Genome Biology</i> , 2020, 21, 264.	8.8	3
14	Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy. <i>iScience</i> , 2020, 23, 101458.	4.1	15
15	The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. <i>Frontiers in Oncology</i> , 2020, 10, 558932.	2.8	15
16	THE PRESENT AND FUTURE OF THE MASS SPECTROMETRY-BASED INVESTIGATION OF THE EXOSOME LANDSCAPE. <i>Mass Spectrometry Reviews</i> , 2020, 39, 745-762.	5.4	18
17	Nuclear Receptors in Cancer Inflammation and Immunity. <i>Trends in Immunology</i> , 2020, 41, 172-185.	6.8	19
18	Targeting tumor microenvironment in ovarian cancer: Premise and promise. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188361.	7.4	105

#	ARTICLE	IF	CITATIONS
19	Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. <i>Oncogene</i> , 2020, 39, 4227-4240.	5.9	30
20	Nuclear receptors: recent drug discovery for cancer therapies. <i>Endocrine Reviews</i> , 2019, 40, 1207-1249.	20.1	65
21	Surgical stress and cancer progression: the twisted tango. <i>Molecular Cancer</i> , 2019, 18, 132.	19.2	117
22	Targeting Metabolic Redox Circuits for Cancer Therapy. <i>Trends in Biochemical Sciences</i> , 2019, 44, 401-414.	7.5	138
23	RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. <i>Npj Precision Oncology</i> , 2019, 3, 13.	5.4	23
24	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	11.9	158
25	Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. <i>Neoplasia</i> , 2019, 21, 363-375.	5.3	27
26	A Novel Autocrine CXCL14/ACKR2 Axis: The Achilles' Heel of Cancer Metastasis?. <i>Clinical Cancer Research</i> , 2019, 25, 3476-3478.	7.0	11
27	Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. <i>Oncogene</i> , 2019, 38, 2305-2319.	5.9	41
28	Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3673-E3681.	7.1	56
29	The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts. <i>Genome Biology</i> , 2018, 19, 35.	8.8	68
30	Nuclear lactate dehydrogenase A senses ROS to produce α -hydroxybutyrate for HPV-induced cervical tumor growth. <i>Nature Communications</i> , 2018, 9, 4429.	12.8	115
31	Epigenetics in ovarian cancer: premise, properties, and perspectives. <i>Molecular Cancer</i> , 2018, 17, 109.	19.2	87
32	A mass spectrometric insight into the origins of benign gynecological disorders. <i>Mass Spectrometry Reviews</i> , 2017, 36, 450-470.	5.4	16
33	Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 1369-1382.	0.9	184
34	MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. <i>Oncology Letters</i> , 2017, 13, 4039-4046.	1.8	37
35	LncRNAs: the bridge linking RNA and colorectal cancer. <i>Oncotarget</i> , 2017, 8, 12517-12532.	1.8	33
36	Tumor microenvironment: The culprit for ovarian cancer metastasis?. <i>Cancer Letters</i> , 2016, 377, 174-182.	7.2	149

#	ARTICLE	IF	CITATIONS
37	Menopause-induced uterine epithelium atrophy results from arachidonic acid/prostaglandin E2 axis inhibition-mediated autophagic cell death. <i>Scientific Reports</i> , 2016, 6, 31408.	3.3	26
38	Complementing the tumor-specific immunity in tumor radiotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 289-289.	1.7	0
39	Increased expression of fibroblast growth factor receptor 1 in endometriosis and its correlation with endometriosis-related dysmenorrhea and recurrence. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 117-124.	1.1	13
40	MicroRNAs in colorectal cancer: Small molecules with big functions. <i>Cancer Letters</i> , 2015, 360, 89-105.	7.2	80
41	Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. <i>Mass Spectrometry Reviews</i> , 2013, 32, 267-311.	5.4	15
42	The expression and functionality of stromal caveolin 1 in human adenomyosis. <i>Human Reproduction</i> , 2013, 28, 1324-1338.	0.9	28
43	Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 202-215.	1.1	11
44	Proteomics Identification of Annexin A2 as a Key Mediator in the Metastasis and Proangiogenesis of Endometrial Cells in Human Adenomyosis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M112.017988-1-M112.017988-24.	3.8	77
45	Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation. <i>Cancer Letters</i> , 2012, 318, 14-25.	7.2	16
46	Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. <i>Cancer Letters</i> , 2012, 323, 115-127.	7.2	115
47	Hypoxia: The driving force of uterine myometrial stem cells differentiation into leiomyoma cells. <i>Medical Hypotheses</i> , 2011, 77, 985-986.	1.5	28
48	Viral proteomics: The emerging cutting-edge of virus research. <i>Science China Life Sciences</i> , 2011, 54, 502-512.	4.9	19
49	The metabolic switch and its regulation in cancer cells. <i>Science China Life Sciences</i> , 2010, 53, 942-958.	4.9	18